Navigation Links
K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission
Date:12/27/2010

ST. LOUIS, Dec. 27, 2010 /PRNewswire-FirstCall/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its Form 10-K for its fiscal year ended March 31, 2010 with the Securities and Exchange Commission.  As a result, the Company has met the deadline for filing its delayed fiscal 2010 Form 10-K to enable its securities to continue trading on the New York Stock Exchange.

The Company is currently working on preparing and filing its quarterly reports on Form 10-Q for the quarters ended June 30, 2010 and September 30, 2010 and will file these reports as soon as they are completed.  The Company's Form 10-Q for the quarter ending December 31, 2010 will be due on February 9, 2011.  The Company currently expects that it will be unable to timely file this report.

Greg Divis, KV's Chief Executive Officer stated, "We are pleased to have filed our Form 10-K for fiscal 2010 and continue to work diligently and as quickly as possible to file the remaining outstanding quarterly reports to enable us to return to a current and timely filer with the Securities and Exchange Commission.  The Company continues to move forward as we focus on returning additional products to the market prior to our 2011 fiscal year-end and to the approval and launch of Gestiva™."

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded prescription pharmaceutical products.  The company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.  For further information about K-V Pharmaceutical Company, please visit the company's corporate Web site at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

This press releases contains various
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah Associates ... providing a summary of the 2015 marketplace exchange ... trends.  According to a recent ... and Evaluation, Department of Health and Human Services) ... in individual medical plans through the Marketplace as ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... Radiation Therapy Services Holdings, Inc. (the “Company”), a ... for the first quarter ended March 31, 2011. ... million, an increase of 16.4% compared to $134.5 million in ... revenue was principally due to revenue from the May 2010 ...
... EDGE, N.J., May 11, 2011 Nephros, Inc. (OTC ... company developing and marketing filtration products for therapeutic applications, ... May 10, 2011 the Company received approval from the ... regulatory agency, to market its Dual Stage Ultrafilters (DSU) ...
Cached Medicine Technology:Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 2Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 3Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 4Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 5Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 6Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 7Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 8Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 9Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 10Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 11Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 2Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 3Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 4
(Date:12/22/2014)... Physicians in China are most eagerly awaiting ... non-Hodgkin’s lymphoma (NHL), according to a new report from ... firm. MabThera is the only biologic available to treat ... of NHL. , According to Kantar Health’s report, “Biosimilars ... NHL in China has been growing and is expected ...
(Date:12/22/2014)... Only weeks following the announcement that ... to have a battery manufacturer create 29 well-paying jobs ... ) is launching in Henderson to deliver yet ... strong manufacturing sector is going to build a stronger ... “and TalkLocal works with small businesses that rely on ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... , GAITHERSBURG, Md., Sept. 21 ... Services (HHS) has placed an order for an additional 29 million ... H1N1 influenza virus. This brings HHS orders to date to ... value of approximately $453 million. Previous HHS orders for approximately ...
... patients more likely to finish radiation course, study finds ... interrupted radiation treatment is a common problem among Medicare ... has found. , Researchers analyzed data from 5,086 Medicare ... and 2003 and found that nearly 40 percent of ...
... around the country, care is delayed, complicated and ... the same language. The situation is particularly dire ... York. Now, USC computer scientists, communication specialists ... robust and effective speech-to-speech (S2S) translation system for ...
... 2009 Results of a multicenter study in ... low rate of complications in diabetic patients, will be ... scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). ... on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter ...
... put your waistline at risk, according to a new study ... how other peoples, weight and food choices influence how much ... concern," write authors Brent McFerran, Darren W. Dahl (both University ... Morales (Arizona State University). "We decided to investigate how someone,s ...
... , NEW YORK, Sept. 21 PricewaterhouseCoopers, ... explore the business implications of one of the greatest domestic policy ... As the debate continues to rage in Washington, health industry ... upcoming PwC webcast series entitled 360 Degree Insight will ...
Cached Medicine News:Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 2Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 3Health News:Head, Neck Cancer Treatment Often Not Completed 2Health News:'The doctor can understand you now' 2Health News:'The doctor can understand you now' 3Health News:Researchers find drug-eluting stents safe, effective for PCI in diabetics 2Health News:Watching your weight? Beware of skinny friends with big appetites 2Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 2Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 3Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 4
Cytomegalovirus IgM ELISA....
Small Incision Microforceps: Tano ILM Forceps...
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Microforceps: Claes ILM Forceps...
Medicine Products: